Interestingly, however, although the anti‐CD73 antibody TY/23 has been shown to inhibit primary tumor growth in a adenosine‐dependent manner [14], TY/23 compared to the small molecule inhibitor of CD73 (APCP) was superior in combination with the A2AR antagonist (A2ARi) with regard to metastatic control [16, 43]. The gene discussed is ADORA2A; the disease is neoplasm.